DCUN1D1 and cancer: Interestingly, these data are in agreement with the lower activity of NAcM-OPT compared to MLN4924 in different cancer cell lines using this DCN1 inhibitor [53, 66], suggesting a need to further improve the binding affinities to DCN1 and the efficacy for these novel class of compounds.